Kimberly Allison

Publication Details

  • Biomarkers of progestin therapy resistance and endometrial hyperplasia progression AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY Upson, K., Allison, K. H., Reed, S. D., Jordan, C. D., Newton, K. M., Swisher, E. M., Doherty, J. A., Garcia, R. L. 2012; 207 (1)


    We sought to identify biomarkers associated with progestin therapy resistance and persistence/progression of endometrial hyperplasia.We performed a nested case-control study among women with complex (n = 73) and atypical (n = 41) hyperplasia treated with oral progestin, followed up 2-6 months for persistence/progression. We evaluated index endometrial protein expression for progesterone receptor isoform A, progesterone receptor isoform B (PRB), PTEN, Pax-2, and Bcl-2. Odds ratios and 95% confidence intervals (CIs) were estimated.Among women with atypical hyperplasia, high PRB expression was associated with 90% decreased risk of persistence/progression (95% CI, 0.01-0.8). High expression of progesterone receptor A and PRB suggested decreased risk of persistence/progression (odds ratio, 0.1; 95% CI, 0.02-1.0). These findings were not observed among women with complex hyperplasia. No associations were found with PTEN, Pax-2, and Bcl-2 protein expression.PRB expression shows promise as a biomarker of progestin response. Further research is warranted to understand how PRB expression may guide treatment decisions.

    View details for DOI 10.1016/j.ajog.2012.05.012

    View details for Web of Science ID 000305755000013

    View details for PubMedID 22727345

Stanford Medicine Resources:

Footer Links: